Literature DB >> 17322125

Sphingosine-1-phosphate/sphingosine kinase pathway is involved in mouse airway hyperresponsiveness.

Fiorentina Roviezzo1, Annarita Di Lorenzo, Mariarosaria Bucci, Vincenzo Brancaleone, Valentina Vellecco, Marilisa De Nardo, Donatella Orlotti, Raffaele De Palma, Francesco Rossi, Bruno D'Agostino, Giuseppe Cirino.   

Abstract

Sphingosine-1-phosphate (S1P) has been shown to regulate numerous and diverse cell functions, including smooth muscle contraction. Here we assessed the role of S1P/Sphingosine kinase (SPK) pathway in the regulation of bronchial tone. Our objective was to determine, using an integrated pharmacologic and molecular approach, (1) the role of S1P as endogenous modulator of the bronchial tone, and (2) the linkage between S1P pathway and bronchial hyperresponsiveness. We evaluated S1P effects on isolated bronchi and whole lungs, harvested from Balb/c mice sensitized to ovalbumin (OVA) versus vehicle-treated mice, by measuring bronchial reactivity and lung resistance. We found that S1P administration on nonsensitized mouse bronchi does not cause any direct effect on bronchial tone, while a significant increase in Ach-induced contraction occurs after S1P challenge. Conversely, in OVA-sensitized mice S1P/SPK pathway triggers airway hyperesponsiveness. Indeed, S1P causes a dose-dependent contraction of isolated bronchi. Similarly, in the whole lung system S1P increased airway resistance only in OVA-sensitized mice. The action on bronchi of S1P is coupled to an enhanced expression of SPK(1) and SPK(2) as well as of S1P(2) and S1P(3) receptors. In these experiments the key role for S1P/SPK in hyperreactivity has been confirmed by pharmacologic modulation of SPKs. S1P/SPK pathway does not seem to play a major role in physiologic conditions, while it may become critical in pathologic conditions. These results open new windows for therapeutic strategies in diseases like asthma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322125     DOI: 10.1165/rcmb.2006-0383OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  41 in total

1.  Pulmonary endothelial cell barrier enhancement by novel FTY720 analogs: methoxy-FTY720, fluoro-FTY720, and β-glucuronide-FTY720.

Authors:  Sara M Camp; Eddie T Chiang; Chaode Sun; Peter V Usatyuk; Robert Bittman; Viswanathan Natarajan; Joe G N Garcia; Steven M Dudek
Journal:  Chem Phys Lipids       Date:  2015-08-10       Impact factor: 3.329

2.  Regulator of G-protein signaling-5 inhibits bronchial smooth muscle contraction in severe asthma.

Authors:  Zhao Yang; Nariman Balenga; Philip R Cooper; Gautam Damera; Richard Edwards; Christopher E Brightling; Reynold A Panettieri; Kirk M Druey
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

Review 3.  Sphingolipids in inflammation: pathological implications and potential therapeutic targets.

Authors:  Graeme F Nixon
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

4.  Functional variants of the sphingosine-1-phosphate receptor 1 gene associate with asthma susceptibility.

Authors:  Xiaoguang Sun; Shwu-Fan Ma; Michael S Wade; Carlos Flores; Maria Pino-Yanes; Jaideep Moitra; Carole Ober; Rick Kittles; Aliya N Husain; Jean G Ford; Joe G N Garcia
Journal:  J Allergy Clin Immunol       Date:  2010-07-10       Impact factor: 10.793

5.  Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Authors:  Shailendra R Singh; Nikol Sullo; Maria Matteis; Giuseppe Spaziano; John McDonald; Ruth Saunders; Lucy Woodman; Konrad Urbanek; Antonella De Angelis; Raffaele De Palma; Rachid Berair; Mitesh Pancholi; Vijay Mistry; Francesco Rossi; Remo Guerrini; Girolamo Calò; Bruno D'Agostino; Christopher E Brightling; David G Lambert
Journal:  Br J Pharmacol       Date:  2016-03-06       Impact factor: 8.739

6.  FTY720 (s)-phosphonate preserves sphingosine 1-phosphate receptor 1 expression and exhibits superior barrier protection to FTY720 in acute lung injury.

Authors:  Lichun Wang; Saad Sammani; Liliana Moreno-Vinasco; Eleftheria Letsiou; Ting Wang; Sara M Camp; Robert Bittman; Joe G N Garcia; Steven M Dudek
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

7.  Blockage of sphingosine-1-phosphate receptor 2 attenuates allergic asthma in mice.

Authors:  Soo-Jin Park; Dong-Soon Im
Journal:  Br J Pharmacol       Date:  2019-03-14       Impact factor: 8.739

Review 8.  The role of sphingosine-1-phosphate and its receptors in asthma.

Authors:  John J Ryan; Sarah Spiegel
Journal:  Drug News Perspect       Date:  2008-03

Review 9.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 10.  Sphingosine-1-phosphate, FTY720, and sphingosine-1-phosphate receptors in the pathobiology of acute lung injury.

Authors:  Viswanathan Natarajan; Steven M Dudek; Jeffrey R Jacobson; Liliana Moreno-Vinasco; Long Shuang Huang; Taimur Abassi; Biji Mathew; Yutong Zhao; Lichun Wang; Robert Bittman; Ralph Weichselbaum; Evgeny Berdyshev; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.